Currently out of the existing stock ratings of Matt Miksic, 221 are a BUY (81.85%), 36 are a HOLD (13.33%), 13 are a SELL (4.81%).

Matt Miksic

Work Performance Price Targets & Ratings Chart

Analyst Matt Miksic, currently employed at BARCLAYS, carries an average stock price target met ratio of 57.67% that have a potential upside of 18.57% achieved within 278 days.

Matt Miksic’s has documented 570 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PODD, Insulet at 11-Nov-2024.

Wall Street Analyst Matt Miksic

Analyst best performing recommendations are on HSIC (HENRY SCHEIN).
The best stock recommendation documented was for ISRG (INTUITIVE SURGICAL) at 10/18/2022. The price target of $235 was fulfilled within 7 days with a profit of $41.27 (21.3%) receiving and performance score of 30.43.

Average potential price target upside

of $47.3 (14.39%) on ISRG (INTUITIVE SURGICAL).
of $37.16 (19.07%) on SYK (STRYKER).
of $32.98 (29.92%) on JNJ (JOHNSON & JOHNSON).

ABT Abbott Laboratories ALC Alcon AG BAX Baxter International BSX Boston Scientific Corp EW Edwards Lifesciences Corp GMED Globus Medical HSIC Henry Schein IART Integra LifeSciences Holdings JNJ Johnson & Johnson MDT Medtronic PLC NUVA NuVasive ORGO Organogenesis Holdings SHC Sotera Health Co SYK Stryker WMGI Wright Medical Group N.V XRAY Dentsply Sirona ZBH Zimmer Biomet Holdings ALGN Align Technology DXCM DexCom PODD Insulet TNDM Tandem Diabetes Care ISRG Intuitive Surgical INMD InMode Ltd ZIMV ZimVie BLCO Bausch + Lomb Corp LIVN LivaNova PLC PDCO Patterson Companies SDC SmileDirectClub

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Matt Miksic (BARCLAYS)